[
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=9c7aea4398fc2351a84cbd2bc24067f288ef269f666a0d7793f7e0cca16954aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758235805,
      "headline": "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know",
      "id": 136818421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=9c7aea4398fc2351a84cbd2bc24067f288ef269f666a0d7793f7e0cca16954aa"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5be2b54f7f44fa2c32b109ad2118a76966fb90459b131a3e6093929ca0f4ac24",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758213420,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 136869677,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5be2b54f7f44fa2c32b109ad2118a76966fb90459b131a3e6093929ca0f4ac24"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
    "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=8ab7990096c453b45022474ea5f79a54f328e2640407da375438ee40c81610e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758204004,
      "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
      "id": 136799645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=8ab7990096c453b45022474ea5f79a54f328e2640407da375438ee40c81610e2"
    }
  },
  {
    "ts": null,
    "headline": "Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer",
    "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c",
    "url": "https://finnhub.io/api/news?id=d020eb28f523abba10ce4059b59afced37a0d5c943f01a323839a817178f4189",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758196800,
      "headline": "Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer",
      "id": 136797741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c",
      "url": "https://finnhub.io/api/news?id=d020eb28f523abba10ce4059b59afced37a0d5c943f01a323839a817178f4189"
    }
  },
  {
    "ts": null,
    "headline": "Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management",
    "summary": "SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (\"Fangzhou\" or the \"Company\") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil",
    "url": "https://finnhub.io/api/news?id=4f4a99feab999cb27b30fbd0624a8238ba34037110192fc6d1dbb4b9153e5958",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758161760,
      "headline": "Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management",
      "id": 136797742,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (\"Fangzhou\" or the \"Company\") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil",
      "url": "https://finnhub.io/api/news?id=4f4a99feab999cb27b30fbd0624a8238ba34037110192fc6d1dbb4b9153e5958"
    }
  }
]